1483 / 1851
To date, waiting for definitive results of randomised studies
(HD0607 and GD0801) patients
treated with ABVD x 6 should
receive consolidative ISRT to bulky site at baseline
Patients
treated with more intensive chemotherapy
(
BEACOPPescalated x 6) need
additional RT only to PET+
residual disease
according to GHSG HD15.
Patients with
residual focal lesions
after chemotherapy should be
considered for
a sequential ISRT
, with no regard to the
chemotherapy schedule adopted (ABVD or BEACOPP)
Multidisciplinary discussion
is strongly recommended to offer
the best treatment solution to each patient
Take Home Message (Advanced Stage HL)